Actions

Extra: Difference between revisions

From haematologyetc.co.uk

No edit summary
No edit summary
Line 94: Line 94:


----
----
summary tables 
1. expression by acute leukaemias and by haematogones file
freq  pro-b all 
hi  early pre-b all 
hi  pre-b all 
hi  early b all 
rare  pro-t all 
rare  mature-t all 
rare  aml  * 
hi  haemato-gones
2. expression by b-lymphoproliferative disorders
hi cll * 
hi  pll** 
hi  mcl 
hi  fl 
hi  hcl** 
hi  hclv 
hi  mzl 
poss  lpl 
rare  pcs 
*  typically weak  **  typically strong

Revision as of 11:30, 5 June 2023


Summary
CD79b is a pan-B-cell marker expressed from their early commitment to B-cell lineage becoming lost during plasma cell differentiation; CD79b may be used as marker of B-cel lineage, but its more variable expression make it less useful than CD79a or CD19 in this context
The major diagnostic value of CD79b is its characteristically weak-expression in CLL



Normal expression and function

The two forms of CD79 (CD79a and CD79b) each associate directly with the immunoglobulin chains to control signalling from the B-cell receptor. Expression of both CD79a and CD79b is therefore acquired at early B-lymphocyte formation (initially in cytoplasm then membrane) and persist until plasma cell differentiation. However, while both CD79a and CD79b may be considered pan B-cell antigens, expression of CD79b is acquired later and is lost earlier than for CD79a.



Diagnostic role

  • The most useful attribute of CD79b is its variable intensity of expression - in particular the characteristically weak intensity of expression of CD79b in CLL is often used as a diagnostic criterion




SUMMARY TABLES


Note The colour and % refer to the proportion of cases expressing the marker. Additional comments on strength, or site of expression (if relevant) are given below the table. For full details of key click here. For further information about a particular disease state click <I> adjacent to the condition name


Expression in primitive cell types
AML CMML B ALL Burkitt T ALL ETP ALL <I> MPAL <I> Hgns <I>
? <5% 5-20% 20-40% 40-80% 80-100% ? <5% 5-20% 20-40% 40-80% 80-100% ? <5% 5-20% 20-40% 40-80% 80-100% ? <5% 5-20% 20-40% 40-80% 80-100% ? <5% 5-20% 20-40% 40-80% 80-100% ? <5% 5-20% 20-40% 40-80% 80-100% ? <5% 5-20% 20-40% 40-80% 80-100% ? <5% 5-20% 20-40% 40-80% 80-100%

Notes: xxxxx


Expression in mature B cell neoplasms
CLL MCL FL MZL HCL DLBCL LPL PCL
? <5% 5-20% 20-40% 40-80% 80-100% ? <5% 5-20% 20-40% 40-80% 80-100% ? <5% 5-20% 20-40% 40-80% 80-100% ? <5% 5-20% 20-40% 40-80% 80-100% ? <5% 5-20% 20-40% 40-80% 80-100% ? <5% 5-20% 20-40% 40-80% 80-100% ? <5% 5-20% 20-40% 40-80% 80-100% ? <5% 5-20% 20-40% 40-80% 80-100%

Notes: xxxxx


Expression in mature T cell neoplasms*
ATLL CTCL/Sezary T-PLL T-LGL NK-LGL
? <5% 5-20% 20-40% 40-80% 80-100% ? <5% 5-20% 20-40% 40-80% 80-100% ? <5% 5-20% 20-40% 40-80% 80-100% ? <5% 5-20% 20-40% 40-80% 80-100% ? <5% 5-20% 20-40% 40-80% 80-100%

Notes: xxxxx


summary tables

1. expression by acute leukaemias and by haematogones file freq pro-b all hi early pre-b all hi pre-b all hi early b all rare pro-t all rare mature-t all rare aml * hi haemato-gones

2. expression by b-lymphoproliferative disorders hi cll * hi pll** hi mcl hi fl hi hcl** hi hclv hi mzl poss lpl rare pcs

  • typically weak ** typically strong